Catalog No.
Product Name
Application
Product Information
Citations
-
KRAS Inhibitor
KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS with an IC50 of less than 100 nM for KRas G12V, KRas WT, and KRas G12R mutants. This compound demonstrates substantial biological activity in disrupting KRAS-mediated signaling pathways. KRAS inhibitor-24 is utilized in preclinical research to study KRAS-driven tumors and to investigate potential therapeutic strategies targeting KRAS mutations in various cancers. -
KRAS Inhibitor
(1R)-KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS, demonstrating an IC50 of less than 100 nM for KRas G12V, KRas Wild Type, and KRas G12R variants. This inhibitor serves as a valuable tool for research applications focused on KRAS-driven cancers, providing insights into signaling pathways and potential therapeutic modalities targeting this critical oncogene. -
KRAS G12D Inhibitor
KRAS G12D-IN-31 is a potent inhibitor of the KRAS G12D mutation, exhibiting an IC50 of less than 100 nM. It effectively inhibits the proliferation of RAS-dependent cancer cells, including those harboring KRAS G12C, KRAS G12D, KRAS G12V, and KRASWT. This compound is particularly valuable for research applications involving non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma, facilitating the exploration of KRAS-targeted therapies. -
RAS Ligand
VVD-849 is a RAS ligand that covalently binds to Cys242 in the RAS-binding domain of PI3K p110α, facilitating the interaction between RAS and PI3K. This compound exhibits partial inhibition of pAKT (S473) specifically in HER2-overexpressing tumors. VVD-849 is utilized in cancer research, particularly for studying the mechanisms underlying breast cancer progression and RAS-related signaling pathways. -
KRAS(G12D) Inhibitor
TH-Z827 is a selective inhibitor of the KRAS(G12D) mutant, demonstrating an IC50 of 2.4 μM. This compound does not interact with wild-type KRAS or the KRAS(G12C) variant. TH-Z827 effectively disrupts the interaction between KRAS(G12D) and CRAF, with an IC50 value of 42 μM, making it a valuable tool for studying KRAS-driven cancers and developing targeted therapies. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 3 TFA is a selective inhibitor targeting the KRAS G12D mutation, exhibiting an IC50 of less than 500 nM. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research related to KRAS-driven malignancies. Additionally, KRAS G12D Inhibitor 3 TFA features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), thus facilitating the development of bioconjugates and other applications in chemical biology. -
Lbc-RhoA Interaction Inhibitor
(E/Z)-ZINC09659342 is a potent inhibitor of the Lbc-RhoA protein interaction, impacting RhoA-mediated cellular signaling pathways. This compound is valuable for studies focused on RhoA's role in cell adhesion, migration, and cytoskeletal dynamics. It serves as a useful tool for researchers investigating the molecular mechanisms of various diseases associated with RhoA dysregulation. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 14 is a potent inhibitor specifically targeting the KRAS G12C mutation, with an IC50 value of 18 nM. This compound effectively disrupts the activity of the KRAS protein, making it a valuable tool for studies on cancer biology, particularly in models of tumors driven by KRAS mutations. Its application extends to drug discovery and development efforts aimed at novel therapeutic strategies for KRAS-driven malignancies. -
ADT-007 Prodrug
ADT-1004 is an orally active prodrug of the pan-RAS inhibitor ADT-007, which is characterized by its reversible, high potency and selectivity. By binding to the nucleotide-free conformation of RAS proteins, ADT-007 effectively inhibits GTP activation, subsequently blocking downstream MAPK and AKT signaling pathways. ADT-1004 is primarily utilized in research focused on pancreatic ductal adenocarcinoma, providing a valuable tool for the investigation of RAS-mediated oncogenic processes. -
KRAS(G12C) PROTAC
PROTAC KRAS G12C degrader-2 is a bifunctional molecule that targets the KRAS G12C mutant protein for degradation via the proteasome. It features a cereblon inhibitor that modulates the activity of inhibitors of apoptosis proteins (IAPs) to facilitate the targeted destruction of KRAS. This reagent is valuable for research applications aimed at elucidating the role of KRAS in cancer biology and developing effective targeted therapies for KRAS-driven malignancies. -
MRTF/SRF Inhibitor
MRTF/SRF-IN-1 is a selective inhibitor of myocardin-related transcription factor and serum response factor (MRTF/SRF). This compound is utilized in research aimed at understanding the role of MRTF/SRF in cancer progression and fibrotic diseases. It has potential applications in studying molecular pathways associated with cellular proliferation and fibrosis. -
Anti-cancer Agent
KRAS G12D inhibitor 8 is a selective inhibitor of the KRAS G12D oncogene, a key member of the Ras protein family involved in critical intracellular signaling pathways that regulate cell growth and development. This compound exhibits potent anti-cancer activity, making it a valuable tool for research focused on KRAS G12D-driven malignancies. Its application in preclinical studies may provide insights into therapeutic strategies targeting KRAS mutations associated with various cancers. -
Farnesyl Transferase Inhibitor
BMS-214662 hydrochloride is a potent farnesyltransferase inhibitor that disrupts the prenylation of Ras proteins, preventing their localization and function at the cell membrane. This inhibition leads to significant anti-tumor activity, making it a valuable tool for cancer research. The compound demonstrates a high affinity for H-Ras with an IC50 of 1.3 nM and for K-Ras with an IC50 of 8.4 nM, highlighting its potential in studying tumorigenesis associated with Ras signaling pathways. -
GGTase I Inhibitor
GGTI-286 is a selective inhibitor of geranylgeranyl transferase I (GGTase I) with an IC50 of 2 μM, demonstrating 25-fold increased potency compared to its methyl ester derivative. It effectively inhibits the geranylgeranylation of Rap1A while displaying a lower impact on the farnesylation of H-Ras, with IC50 values of 2 μM and >30 μM, respectively. Additionally, GGTI-286 shows strong inhibition of oncogenic K-Ras4B stimulation, with an IC50 of 1 μM, making it a valuable tool for research in cancer biology and signaling pathways. -
Ras Inhibitor
KRAS G12D inhibitor 5 is a selective inhibitor targeting the mutated KRAS G12D protein, a key driver in various malignancies, including pancreatic cancer. This compound is valuable in research applications focusing on the therapeutic mechanisms underlying KRAS-driven tumorigenesis and may help elucidate the pathways involved in cancer progression and resistance. -
KRAS G12C Inhibitor
Sosimerasib is an orally active inhibitor targeting KRAS G12C mutations. It exhibits significant functional inhibitory effects on mutant KRAS G12C proteins, making it a valuable tool for studying signaling pathways involved in cancer progression. This compound is particularly relevant for research applications focused on non-small cell lung cancer. -
KRAS(G12D) Inhibitor
MRTX-EX185 is a selective inhibitor of KRAS(G12D) with an IC50 of 90 nM, effectively binding to both GDP-loaded and active GTP-bound states of KRAS. This compound demonstrates broad-spectrum activity against various KRAS mutations, including KRAS WT, KRAS (G12C), KRAS (Q61H), and KRAS (G13D), with IC50 values ranging from 110 nM to 290 nM. Additionally, MRTX-EX185 interacts with GDP-loaded HRAS. This reagent is valuable for investigating RAS-driven tumors, particularly in the context of pancreatic cancer research. -
K-Ras-G12D Inhibitor
(R)-G12Di-7 is a covalent inhibitor specifically targeting K-Ras-G12D. This compound selectively binds to the K-Ras-G12D·GDP and K-Ras-G12D·GppNHp complexes, effectively labeling them. (R)-G12Di-7 demonstrates significant inhibitory activity against cancer cells harboring the G12D mutation, making it a valuable tool for research into K-Ras-related oncogenic signaling and potential therapeutic interventions. -
KRASG12C Inhibitor
(7R)-Elisrasib is a selective inhibitor targeting the KRASG12C mutation, a key driver in various cancers. This compound demonstrates potent antitumor activity, effectively inhibiting tumor growth in preclinical mouse models. It is primarily used in cancer research focused on KRAS-driven tumors and aids in the investigation of targeted therapies for oncogenic mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 28 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 57 nM. This compound demonstrates significant antitumor activity and is utilized in research focusing on KRAS-driven cancers. Its applications include investigating the therapeutic potential of KRAS inhibition in various oncological studies. -
RAS GTPase Inhibitor
RAS GTPase inhibitor 1 is a specific inhibitor targeting RAS GTPase, known for its significant anti-tumor activity. This compound demonstrates an effective EC50 of less than 1 μM in facilitating nucleotide exchange and an IC50 of less than 1 μM in H727 cancer cells. It is valuable for research applications aimed at understanding RAS signaling pathways and developing targeted cancer therapies. -
KRAS Regulation
KRAS G12D inhibitor 26 is a specific inhibitor targeting the KRAS(G12D) mutation, with an IC50 of ≤ 100 nM. This compound modulates KRAS signaling pathways, making it a valuable tool for studying KRAS-related oncogenic processes. Its application is pivotal in cancer research, particularly in elucidating the mechanisms underlying tumorigenesis and therapeutic resistance in KRAS-driven malignancies. -
Rac GTPase-p67 Inhibitor
p67phox-IN-1 is a specific inhibitor of the interaction between Rac GTPase and the p67phox protein. This compound interferes with the activation of the NADPH oxidase complex, thereby modulating reactive oxygen species production. p67phox-IN-1 serves as a valuable tool in research related to oxidative stress, inflammation, and redox signaling pathways. Its utility extends to studies exploring the role of Rac GTPases in various physiological and pathological processes. -
GIT1/β-Pix PPI Inhibitor
PPI-GIT1/β-Pix PPI-IN-1 is a potent inhibitor of the GIT1/β-Pix protein-protein interaction, exhibiting a KD value of 7.7 µM. By disrupting the GIT/PIX interaction, this compound effectively modulates the activation of downstream Rho GTPases Rac1 and Cdc42, which are critical in various signaling pathways. PPI-GIT1/β-Pix PPI-IN-1 is particularly relevant in cancer research, demonstrating significant inhibitory effects on the metastasis of gastric cancer. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 1 is a potent inhibitor targeting the KRAS G12D mutant with an IC50 of 0.4 nM. It effectively inhibits KRAS G12D-mediated ERK phosphorylation, exhibiting an IC50 of 0.8 nM. This compound is valuable in research focused on cancers driven by KRAS G12D mutations, including pancreatic ductal adenocarcinoma and colorectal cancer. -
KRAS G12D Inhibitor
(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate specifically targets the KRAS G12D mutant protein, functioning as an effective inhibitor. This compound demonstrates significant potential in cancer research, particularly in studies focused on KRAS-driven malignancies. Its application can aid in the investigation of KRAS signaling pathways and the development of targeted therapies for KRAS-related tumors. -
KRAS G12C Inhibitor
KRASG12C IN-13 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant biological activity against advanced solid tumors, particularly non-small cell lung cancer and colorectal cancer. Researchers can utilize KRASG12C IN-13 to investigate therapeutic strategies and resistance mechanisms associated with KRAS-driven malignancies. -
Kras4B G12D Inhibitor
Kras4B G12D-IN-1 is a selective inhibitor of the Kras4B G12D mutant, targeting its oncogenic activity. This compound demonstrates significant anticancer properties by reducing Kras protein expression in mouse embryonic fibroblasts (MEF) harboring the Kras4B G12D mutation. Kras4B G12D-IN-1 is relevant for research investigating Kras-driven cancers and the development of targeted therapies. -
KRASG12D Inhibitor
KRASG12D-IN-3 is a potent inhibitor that specifically targets the KRASG12D mutation. It demonstrates significant anti-proliferative effects on AGS and AsPC-1 cell lines, with IC50 values of 0.38 nM and 1.23 nM, respectively. This compound is valuable for research applications focused on the role of KRAS mutations in cancer biology and therapeutic development. -
Ligand for KRAS G12C for PROTAC
MRTX849 acid serves as a ligand for KRAS G12C, facilitating the synthesis of the PROTAC LC-2. This first-in-class PROTAC effectively induces degradation of endogenous KRAS G12C, demonstrating potent biological activity with DC50 values ranging from 0.25 to 0.76 μM. It is applicable in research settings focused on targeted protein degradation and cancer therapeutics.
-
NRAS G12D Inhibitor
IACS-56676 is a selective inhibitor of the NRAS G12D mutation, with a binding affinity (Kd) of 0.031 μM. It stabilizes the p-loop and preserves critical interactions with key residues, including Asp12, Gly60, and Asp69, allowing for its specificity toward NRAS G12D while sparing wild-type KRAS through targeting Leu95. This compound is applicable in research focusing on melanoma, hematologic malignancies, and thyroid cancer, providing a valuable tool for investigating targeted therapies in these contexts. -
KRAS G12C Inhibitor
(4R)-BBO-8520 is a selective inhibitor of the KRAS G12C mutant. This compound effectively impedes the KRAS G12C (ON) signaling, thereby inhibiting cell proliferation by blocking the interaction with GTP. Additionally, (4R)-BBO-8520 disrupts the RAS-RAF1 interaction, facilitating the return of KRAS G12C to its inactive (OFF) state. It is particularly valuable for research applications focused on cancer biology and therapeutics targeting KRAS-driven malignancies. -
KRAS(G12C) Inhibitor
Spiclomazine is a selective inhibitor of mutant KRAS(G12C), targeting KRAS-driven pancreatic cancer. This compound effectively reduces KRas-GTP levels and inhibits downstream RAS-mediated signaling pathways. In preclinical studies, Spiclomazine demonstrates significant tumor progression inhibition in mouse renal capsule xenotransplantation models, making it a valuable tool for researching therapeutic strategies against KRAS-driven malignancies. -
GGTase I Inhibitor
GGTI-286 hydrochloride is a selective inhibitor of geranylgeranyltransferase I (GGTase I) with a potency that is 25-fold greater than the methyl ester of FTI-276 (IC50 = 2 μM). This compound demonstrates a strong preference for inhibiting the geranylgeranylation of Rap1A over the farnesylation of H-Ras in NIH3T3 cells (IC50s = 2 μM and >30 μM, respectively). Additionally, GGTI-286 hydrochloride effectively inhibits the stimulation of oncogenic K-Ras4B, with an IC50 of 1 μM, making it a valuable tool for research in cancer biology and signal transduction pathways. -
GTP Analogue
6-Thio-GTP is a GTP analogue that serves as a metabolite of the immunosuppressive agent Azathioprine. This nucleotide analogue is significant for its ability to interfere with nucleotide metabolism and modulate cellular signaling pathways. Its applications extend to studies on nucleic acid synthesis, signal transduction, and immune response regulation in various biological systems. -
Fragment of FAM49B
FAM49B (190-198) mouse is a peptide fragment targeting FAM49B, a mitochondria-localized protein involved in the regulation of mitochondrial fission. This peptide plays a critical role in maintaining mitochondrial function and integrity while influencing tumor progression. Additionally, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and modulating cytoskeletal organization, making it a valuable tool for research in cancer biology and immunology. -
S-(-)-perillyl Alcohol Enantiomer
(+) - Perillyl alcohol is the S-(-) enantiomer known for its ability to inhibit polypeptide growth and impede the cell cycle at the G0/G1 phase. This compound modulates cellular signaling pathways linked to alterations in cytoskeletal actin organization. Additionally, (+)-Perillyl alcohol results in decreased expression of key regulatory proteins, including Ras and CDC2 kinase, making it a valuable reagent for studies in cell biology and cancer research. -
Ra Inhibitor
K-Ras-IN-4 is a potent K-Ras inhibitor that specifically targets the K-Ras oncogene, a critical player in cancer cell signaling. This compound effectively impedes K-Ras-mediated signaling pathways, thereby attenuating cell proliferation and survival in K-Ras-driven tumors. K-Ras-IN-4 is utilized in research focused on understanding K-Ras biology and developing targeted therapies for cancers associated with K-Ras mutations. -
Anti-cancer Agent
KRAS G12D Inhibitor 10 is a selective inhibitor targeting the KRAS G12D mutation, a critical driver in various cancers. By inhibiting this variant, the compound demonstrates significant potential for research applications focused on KRAS G12D-mediated oncogenesis. Its role in disrupting the Ras signaling pathway makes it valuable for studies investigating cancer growth and therapeutic resistance mechanisms. -
BAY-293 Negative Control
(S)-BAY-293 serves as a negative control for the potent KRAS-SOS1 interaction inhibitor, BAY 293. This compound is utilized in experimental settings to validate the specificity and efficacy of BAY 293 in studying KRAS signaling pathways. Researchers can use (S)-BAY-293 to ensure experimental results are due to the intended inhibition and not off-target effects. -
KRAS G12C Inhibitor
KRAS inhibitor-6 is a potent inhibitor of the KRAS G12C mutation, specifically designed to selectively target and inhibit this oncogenic driver. Its mechanism of action involves binding to the active site of the mutant KRAS protein, effectively disrupting downstream signaling pathways involved in cellular proliferation and survival. This compound has significant implications for cancer research and therapeutic applications, particularly in the treatment of KRAS-driven tumors. -
KRAS G12C Inhibitor
KRAS inhibitor-8 is a selective inhibitor targeting the KRAS G12C mutation, known for its role in various cancers. This compound demonstrates significant biological activity by effectively disrupting KRAS signaling pathways, leading to reduced tumor growth in KRAS-driven malignancies. KRAS inhibitor-8 is ideal for research in cancer biology and drug discovery focused on mutant KRAS therapeutics. -
KRAS G12C Inhibitor
KRAS inhibitor-7 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates significant inhibition of KRAS G12C activity, making it a valuable tool for studying oncogenic signaling pathways involving KRAS mutations. Its primary applications include cancer research, particularly in the development of targeted therapies for KRAS-driven tumors. -
Ras Inhibitor
KRAS mutant protein inhibitor 1 selectively targets and inhibits the activity of mutant KRAS proteins. Its primary mechanism involves disruption of KRAS-mediated signaling pathways, which are critical in various cancers. This compound is valuable for research applications focused on understanding the role of KRAS mutations in tumorigenesis and exploring potential therapeutic strategies for KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 32 is a potent inhibitor targeting the KRAS G12C mutation. This eight-membered heterocyclic compound demonstrates strong inhibitory activity, which is critical for studies focusing on cancer therapeutics associated with KRAS mutations. It is primarily utilized in research exploring the mechanisms of KRAS-driven malignancies and the development of targeted therapies. -
Racemate of D3S-001
(Rac)-D3S-001 is a racemic mixture of the compound D3S-001, which serves as a potent modulator of specific biological pathways. This compound exhibits significant activity in regulating cellular processes, making it a valuable tool for investigating the underlying mechanisms of disease. It is particularly useful in pharmacological studies and in the development of therapeutic strategies targeting related biological systems. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 18 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-tumor activity, making it valuable for cancer research focused on KRAS-driven malignancies. It is suitable for studies investigating the therapeutic potential of KRAS inhibition in oncogenesis and treatment resistance. -
KRas Inhibitor
KRAS Inhibitor-20 is a small molecule inhibitor targeting the oncogenic mutant KRasG12C. It demonstrates potent inhibitory activity with an IC50 value of less than 10 nM, making it an effective tool for studying KRas-driven malignancies. This compound is valuable for research applications focused on cancer biology, offering insights into therapeutic strategies for KRas-related tumors. -
KRAS G12C Inhibitor
KRAS Inhibitor-16 is a selective inhibitor targeting the KRAS G12C mutation, demonstrating a potent activity with an IC50 of 0.457 µM. This compound effectively inhibits phosphorylated ERK in MIA PaCA-2 and A549 cell lines, with IC50 values of 3.06 µM and 11.1 µM, respectively. KRAS Inhibitor-16 is suitable for research applications focusing on pancreatic, colorectal, and lung cancers, contributing to the advancement of targeted therapies in these malignancies. -
Ras Inhibitor
KRAS inhibitor-4 (compound F12) is a potent inhibitor targeting KRAS, a critical regulator of cell signaling pathways. This compound exhibits significant anticancer activity by disrupting KRAS-mediated signaling, thereby inhibiting tumor growth and proliferation. It is a valuable tool for research focused on cancer biology and therapeutic development related to KRAS mutations.
